MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Cassava Sciences Inc

Closed

SectorHealthcare

1.65

Overview

Share price change

24h

Current

Min

1.59

Max

1.69

Key metrics

By Trading Economics

Income

346K

-28M

EPS

-0.57

Employees

30

EBITDA

1.4M

-30M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+20.48% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

-49M

71M

Previous open

1.65

Previous close

1.65

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Cassava Sciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 wrz 2024, 10:48 UTC

Major Market Movers

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims

28 cze 2024, 20:15 UTC

Major Market Movers

Cassava Sciences' Shares Down 46% After Adviser Is Indicted

27 wrz 2024, 18:36 UTC

Earnings

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27 wrz 2024, 09:15 UTC

Hot Stocks

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

Peer Comparison

Price change

Cassava Sciences Inc Forecast

Price Target

By TipRanks

20.48% upside

12 Months Forecast

Average 2 USD  20.48%

High 2 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forCassava Sciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

1.37 / 1.66Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.